Skip to Content

Birth Weight Modifies Link Between Adult IGF-1 Levels, T2DM

TUESDAY, March 2, 2021 -- Birth weight modifies the association between adulthood levels of circulating insulin-like growth factor-1 (IGF-1) and development of type 2 diabetes (T2D), with an inverse association seen among those with a birth weight ≥2.5 kg, according to a study published online March 1 in BMJ Open Diabetes Research & Care.

Tingting Geng, from the National University of Singapore, and colleagues examined the interaction between circulating IGF-1 and birth weight in relation to T2D in a cohort of 181,090 adults, aged 39 to 70 years, in the U.K. Biobank Study. A chemiluminescent immunoassay method was used to determine serum IGF-1 levels.

During an average follow-up of 9.9 years, the researchers identified 3,299 incident T2D cases. IGF-1 levels were inversely associated with T2D risk in a dose-dependent manner among participants with a birth weight ≥2.5 kg. In contrast, no significant association was seen among those with a birth weight <2.5 kg. There was no interaction noted for the genetic risk score of birth weight with IGF-1 levels in relation to T2D risk.

"Our data indicate that the relation between adulthood IGF-1 and T2D is significantly modified by birth weight," the authors write. "Our findings highlight the importance of early-life risk factors in the development of the lifecourse prevention strategies targeting on IGF-1 and T2D."

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Read this next

Vaccinating Lactating Mothers May Protect Infants From COVID-19

WEDNESDAY, April 21, 2021 -- Antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are detectable in the breast milk of lactating women up to 80 days...

No Link Found for Exposure to Epidural Labor Analgesia and Autism

TUESDAY, April 20, 2021 -- Exposure to epidural labor analgesia (ELA) is not associated with offspring risk for autism spectrum disorder (ASD), according to a study published...

Gender, Race Affects Access to SGLT2-Inhibitor Therapy for T2DM

MONDAY, April 16, 2021 -- There are racial/ethnic, gender, and socioeconomic disparities apparent in access to sodium-glucose cotransporter 2 (SGLT2) inhibitor treatment for...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.